SEC Form 4 · accession 0001104659-18-023079
INTERCEPT PHARMACEUTICALS, INC. · ICPT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Srinivas Akkaraju
Director
Period of report
Apr 5, 2018
Accepted (ET)
Apr 9, 2018 · 5:10 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001270073
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Apr 5, 2018 | A | 234,375 | $64.00 | A | 234,375 | I | See footnote |
| Common Stock | holding | — | — | — | 14,669 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares held by Samsara BioCapital, L.P. ("Samsara BioCapital"). The reporting person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara BioCapital. The Reporting Person disclaims beneficial ownership of these shares except to the extent of the Reporting Person's pecuniary interest therein.